Evidence map›Paper›PMID 26979530›Full record

ArticleBMC cancer2016

Elevated ratio of MMP2/MMP9 activity is associated with poor response to chemotherapy in osteosarcoma.

Pierre Kunz, Heiner Sähr, Burkhard Lehner, Christian Fischer, Elisabeth Seebach, Jörg Fellenberg

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.0field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 85 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Synthesis andBioconjugate chemistry · 2022
    Article
  15. Article
  16. Metastasis and MAPK Pathways.International journal of molecular sciences · 2022
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Pierre KunzClinic for Orthopedics and Trauma Surgery/Spinal Cord Injury Center; Center for Orthopedics, Trauma Surgery and Spinal Cord Injury, University Hospital Heidelberg, Heidelberg, Germany.
Heiner SährClinic for Orthopedics and Trauma Surgery/Spinal Cord Injury Center; Center for Orthopedics, Trauma Surgery and Spinal Cord Injury, University Hospital Heidelberg, Heidelberg, Germany.
Burkhard LehnerClinic for Orthopedics and Trauma Surgery/Spinal Cord Injury Center; Center for Orthopedics, Trauma Surgery and Spinal Cord Injury, University Hospital Heidelberg, Heidelberg, Germany.
Christian FischerClinic for Orthopedics and Trauma Surgery/Spinal Cord Injury Center; Center for Orthopedics, Trauma Surgery and Spinal Cord Injury, University Hospital Heidelberg, Heidelberg, Germany.
Elisabeth SeebachClinic for Orthopedics and Trauma Surgery/Spinal Cord Injury Center; Center for Orthopedics, Trauma Surgery and Spinal Cord Injury, University Hospital Heidelberg, Heidelberg, Germany.
Jörg FellenbergClinic for Orthopedics and Trauma Surgery/Spinal Cord Injury Center; Center for Orthopedics, Trauma Surgery and Spinal Cord Injury, University Hospital Heidelberg, Heidelberg, Germany. Joerg.Fellenberg@med.uni-heidelberg.de.
University Hospital Heidelberg · DESpinal Injuries Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMatrix metalloproteinases (MMPs) are crucially involved in the regulation of multiple stages of cancer progression. Elevated MMP levels have been associated with the development of metastases and poor prognosis in several types of cancer. However, the role of MMPs in osteosarcoma and their prognostic value is still unclear. Available data are conflicting, most likely due to different technical approaches. We hypothesized that in contrast to total mRNA or protein levels frequently analyzed in previous studies the enzymatic activities of MMPs and their inhibitors the tissue inhibitors of matrix metalloproteinases (TIMPs) are closer related to their biological functions. We therefore aimed to evaluate the reliability of different zymography techniques for the quantification of MMP and TIMP activities in osteosarcoma biopsies in order to investigate their distribution, possible regulation and prognostic value.

methodsAll analyses were done using cryo-conserved osteosarcoma pretreatment biopsies (n = 18). Gene and protein expression of MMPs and TIMPs were analyzed by RT-qPCR and western blot analysis, respectively. Overall MMP activity was analyzed by in situ zymography, individual MMP activities were analyzed by gelatin zymography. Reverse zymography was used to detect and quantify TIMP activities.

resultsStrong overall MMP activities could be detected in osteosarcoma pretreatment biopsies with MMP2 and MMP9 as predominant active MMPs. In contrast to total RNA or protein expression MMP2 and MMP9 activities showed significant quantitative differences between good and poor responders. While MMP9 activity was high in the good responder group and significantly decreased in the poor responder group, MMP2 activity showed a reverse distribution. Likewise, significant differences were detected concerning the activity of TIMPs resulting in a negative correlation of TIMP1 activity with MMP2 activity (p = 0.044) and negative correlations of TIMP2 and TIMP3 with MMP9 activity (p = 0.007 and p = 0.006).

conclusionIn contrast to mRNA or protein levels MMP and TIMP activities showed significant differences between the analyzed good and poor responder groups. A shift from MMP9 to predominant MMP2 activity is associated with poor response to chemotherapy suggesting that the ratio of MMP2/MMP9 activity might be a valuable and easily accessible marker to predict the response to chemotherapy in osteosarcoma.

Indexed as

BiopsyCisplatinDoxorubicinFemaleGene Expression Regulation, NeoplasticHumansMaleMatrix Metalloproteinase 2Matrix Metalloproteinase 9MethotrexateOsteosarcomaPrognosisRNA, MessengerTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-2Tissue Inhibitor of Metalloproteinase-3CisplatinDoxorubicinMatrix Metalloproteinase 2Matrix Metalloproteinase 9MethotrexateRNA, MessengerTIMP1 protein, humanTIMP2 protein, humanTIMP3 protein, humanTissue Inhibitor of Metalloproteinase-1Tissue Inhibitor of Metalloproteinase-2Tissue Inhibitor of Metalloproteinase-3ChemotherapyMatrix metalloproteinasesOsteosarcomaPrognosisTissue inhibitor of matrix metalloproteinasesZymography

Identifiers

PMID26979530
PMCPMC4793522
OpenAlexW2296866227

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.